$JNJ

Vanguard value-focused ETFs outperform flat S&P 500 as sector rotation into financials, industrials, and energy accelerates, offering higher dividend yields.

Johnson & Johnson maintains Dividend King status with 63 consecutive years of dividend increases, offering stable income through its diversified healthcare business and AAA credit rating.

J&J plans to divest DePuy Synthes orthopedics unit valued at $20-28 billion. Private equity firms are negotiating potential acquisition bids as part of J&J's portfolio restructuring strategy.

Long-acting HIV injectable therapy significantly outperforms daily pills in Phase 3 trial, showing lower failure rates and improved outcomes for patients with adherence challenges.

FDA grants J&J's Rybrevant Faspro breakthrough designation for HPV-negative head and neck cancer, potentially accelerating patient access to this new treatment option.

Four prominent trial attorneys—Placitella, Rosner, Eglet, and Kline—inducted into 2026 Trial Lawyer Hall of Fame for their decades of litigation experience and significant courtroom achievements.

Scar treatment market to double to $56.3B by 2033, driven by advanced minimally invasive procedures and rising cosmetic demand globally.

J&J's lung cancer therapy Rybrevant Faspro gains FDA approval for accelerated monthly dosing, maintaining efficacy while improving patient convenience and reducing treatment burden.

Hemostasis products market expected to grow from $1.94B to $3.28B by 2035, driven by increased surgeries and trauma cases requiring advanced bleeding control solutions.

Fibrin sealant market to double from $1.60B to $3.57B by 2035, driven by surgical demand and minimally invasive techniques despite accessibility challenges in developing regions.

Global uterine fibroid treatment market projected to grow 7.63% annually through 2033, reaching $9.43 billion. Growth driven by high disease prevalence and minimally invasive surgical advances.